Julie C Stout

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2221111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Profiling Social Cognition in Premanifest Huntington's Disease. Journal of the International Neuropsychological Society, 2022, 28, 217-229.	1.8	5
2	Effectiveness of gait aid prescription for improving spatiotemporal gait parameters and associated outcomes in community-dwelling older people: a systematic review. Disability and Rehabilitation, 2022, 44, 6139-6154.	1.8	6
3	Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?. Lancet Rheumatology, The, 2022, , .	3.9	4
4	Listener Detection of Objectively Validated Acoustic Features of Speech in Huntington's Disease. Journal of Huntington's Disease, 2022, 11, 71-79.	1.9	3
5	Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus. Rheumatology, 2022, 62, 190-199.	1.9	7
6	A qualitative examination of apathy and physical activity in Huntington's and Parkinson's disease. Neurodegenerative Disease Management, 2022, 12, 129-139.	2.2	3
7	The Lived Experiences of Depression in Huntington's Disease: A Qualitative Study. Journal of Huntington's Disease, 2022, 11, 321-335.	1.9	4
8	Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease. Psychological Medicine, 2021, 51, 1338-1344.	4.5	21
9	Feasibility and initial validation of â€~HD-Mobile', a smartphone application for remote self-administration of performance-based cognitive measures in Huntington's disease. Journal of Neurology, 2021, 268, 590-601.	3.6	10
10	Multidimensional Apathy: The Utility of the Dimensional Apathy Scale in Huntington's Disease. Movement Disorders Clinical Practice, 2021, 8, 361-370.	1.5	11
11	The Hunger Games: Homeostatic State-Dependent Fluctuations in Disinhibition Measured with a Novel Gamified Test Battery. Nutrients, 2021, 13, 2001.	4.1	3
12	Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects. Frontiers in Neurology, 2021, 12, 595679.	2.4	6
13	Hippocampal and striatal volumes correlate with spatial memory impairment in Huntington's disease. Journal of Neuroscience Research, 2021, 99, 2948-2963.	2.9	4
14	Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. Brain Communications, 2021, 3, fcab003.	3.3	8
15	Enhancing the Clinical Utility of DriveSafe DriveAware for People with Huntington's Disease. Journal of Huntington's Disease, 2020, 9, 353-357.	1.9	0
16	Gut dysbiosis in Huntington's disease: associations among gut microbiota, cognitive performance and clinical outcomes. Brain Communications, 2020, 2, fcaa110.	3.3	98
17	Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD). Quality of Life Research, 2020, 29, 3419-3439.	3.1	9
18	Accuracy of automated amygdala MRI segmentation approaches in Huntington's disease in the IMAGEâ€HD cohort. Human Brain Mapping, 2020, 41, 1875-1888.	3.6	9

#	Article	IF	CITATIONS
19	Dissociable Motivational Deficits in Pre-manifest Huntington's Disease. Cell Reports Medicine, 2020, 1, 100152.	6.5	16
20	Longitudinal expression changes are weak correlates of disease progression in Huntington's disease. Brain Communications, 2020, 2, fcaa172.	3.3	6
21	Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurology, 2019, 76, 1375.	9.0	44
22	Speech in prodromal and symptomatic Huntington's disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases. Neuroscience and Biobehavioral Reviews, 2019, 107, 450-460.	6.1	32
23	Discrete changes in the frequency and functions of autobiographical reminiscence in Huntington's disease. Memory, 2019, 27, 1345-1351.	1.7	1
24	Striatal morphology and neurocognitive dysfunction in Huntington disease: The IMAGE-HD study. Psychiatry Research - Neuroimaging, 2019, 291, 1-8.	1.8	9
25	How different aspects of motor dysfunction influence dayâ€toâ€day function in huntington's disease. Movement Disorders, 2019, 34, 1910-1914.	3.9	3
26	Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease. Journal of Huntington's Disease, 2019, 8, 467-482.	1.9	17
27	MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1. Brain, 2019, 142, 1876-1886.	7.6	114
28	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. Movement Disorders Clinical Practice, 2019, 6, 541-546.	1.5	67
29	â€~Real-life' hippocampal-dependent spatial memory impairments in Huntington's disease. Cortex, 2019, 119, 46-60.	' 2.4	11
30	Pervasive autobiographical memory impairments in Huntington's disease. Neuropsychologia, 2019, 127, 123-130.	1.6	10
31	Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntington's Disease. Journal of the International Neuropsychological Society, 2019, 25, 453-461.	1.8	6
32	Cognitive Fitness to Drive in Huntington's Disease: Assessing the Clinical Utility of DriveSafe DriveAware. Journal of Huntington's Disease, 2019, 8, 87-95.	1.9	2
33	Spatial memory in Huntington's disease: A comparative review of human and animal data. Neuroscience and Biobehavioral Reviews, 2019, 98, 194-207.	6.1	17
34	A Game for Eliciting Trust Between People and Devices Under Diverse Performance Conditions. Communications in Computer and Information Science, 2018, , 172-190.	0.5	2
35	Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. Journal of Neurology, 2018, 265, 1443-1453.	3.6	7
36	Reduced amygdala volumes are related to motor and cognitive signs in Huntington's disease: The IMAGE-HD study. NeuroImage: Clinical, 2018, 18, 881-887.	2.7	30

#	Article	IF	CITATIONS
37	Rating scales for cognition in Huntington's disease: Critique and recommendations. Movement Disorders, 2018, 33, 187-195.	3.9	38
38	Emotion Recognition Correlates With Social-Neuropsychiatric Dysfunction in Huntington's Disease. Journal of the International Neuropsychological Society, 2018, 24, 417-423.	1.8	21
39	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. NeuroImage: Clinical, 2018, 17, 312-324.	2.7	23
40	Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 194-201.	1.8	42
41	Stages of dysfunctional decision-making in addiction. Pharmacology Biochemistry and Behavior, 2018, 164, 99-105.	2.9	119
42	Relationship between measures of impulsivity in opioid-dependent individuals. Personality and Individual Differences, 2018, 120, 133-137.	2.9	1
43	Oxytocin selectively modulates brain processing of disgust in Huntington's disease gene carriers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 11-16.	4.8	23
44	Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures. Quality of Life Research, 2018, 27, 811-822.	3.1	12
45	Understanding the need for assistance with survey completion in people with Huntington disease. Quality of Life Research, 2018, 27, 801-810.	3.1	1
46	Brain Regions Showing White Matter Loss inÂHuntington's Disease Are Enriched for Synaptic and Metabolic Genes. Biological Psychiatry, 2018, 83, 456-465.	1.3	79
47	E11â€Compensation in huntington's disease. , 2018, , .		0
48	Working Memory-Related Effective Connectivity in Huntington's Disease Patients. Frontiers in Neurology, 2018, 9, 370.	2.4	12
49	Deep Brain Stimulation for Parkinson's disease changes perception in the Rubber Hand Illusion. Scientific Reports, 2018, 8, 13842.	3.3	6
50	Juvenile Huntington's disease: left behind?. Lancet Neurology, The, 2018, 17, 932-933.	10.2	7
51	Testing a longitudinal compensation model in premanifest Huntington's disease. Brain, 2018, 141, 2156-2166.	7.6	33
52	Diminished facial EMG responses to disgusting scenes and happy and fearful faces in Huntington's disease. Cortex, 2018, 106, 185-199.	2.4	10
53	Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?. Quality of Life Research, 2018, 27, 2541-2555.	3.1	10
54	Emotion recognition in Parkinson's disease: Static and dynamic factors Neuropsychology, 2018, 32, 230-234	1.3	9

#	Article	IF	CITATIONS
55	Visual scanning of the eye region of human faces predicts emotion recognition performance in Huntington's disease Neuropsychology, 2018, 32, 356-365.	1.3	7
56	Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease Neuropsychology, 2018, 32, 958-965.	1.3	13
57	Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures Psychological Assessment, 2018, 30, 450-458.	1.5	9
58	Data Analytics from Enrollâ€ <scp>HD</scp> , a Global Clinical Research Platform for Huntington's Disease. Movement Disorders Clinical Practice, 2017, 4, 212-224.	1.5	137
59	Parkinson's disease alters multisensory perception: Insights from the Rubber Hand Illusion. Neuropsychologia, 2017, 97, 38-45.	1.6	25
60	Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington's disease: 30 months IMAGE-HD data. Cortex, 2017, 92, 139-149.	2.4	27
61	Beyond emotion recognition deficits: A theory guided analysis of emotion processing in Huntington's disease. Neuroscience and Biobehavioral Reviews, 2017, 73, 276-292.	6.1	32
62	ldentification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
63	Feasibility and Efficacy of Brief Computerized Training to Improve Emotion Recognition in Premanifest and Early-Symptomatic Huntington's Disease. Journal of the International Neuropsychological Society, 2017, 23, 314-321.	1.8	16
64	Operationalizing compensation over time in neurodegenerative disease. Brain, 2017, 140, 1158-1165.	7.6	62
65	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. JAMA Neurology, 2017, 74, 1352.	9.0	12
66	Design optimization for clinical trials in earlyâ€stage manifest Huntington's disease. Movement Disorders, 2017, 32, 1610-1619.	3.9	11
67	Reduced Willingness to Expend Effort for Reward in Obesity: Link to Adherence to a 3â€Month Weight Loss Intervention. Obesity, 2017, 25, 1676-1681.	3.0	17
68	Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease. Journal of Huntington's Disease, 2017, 6, 201-215.	1.9	1
69	Abnormal Visual Scanning of Emotionally Evocative Natural Scenes in Huntington's Disease. Frontiers in Psychology, 2017, 8, 405.	2.1	1
70	Pilot Validation of Ambulatory Activity Monitors for Sleep Measurement in Huntington's Disease Gene Carriers. Journal of Huntington's Disease, 2017, 6, 249-253.	1.9	20
71	Optokinetic nystagmus reflects perceptual directions in the onset binocular rivalry in Parkinson's disease. PLoS ONE, 2017, 12, e0173707.	2.5	15
72	Cognitive assessment in Huntington disease clinical drug trials. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 227-244.	1.8	13

#	Article	IF	CITATIONS
73	Families Affected by Huntington's Disease Report Difficulties in Communication, Emotional Involvement, and Problem Solving. Journal of Huntington's Disease, 2017, 6, 169-177.	1.9	13
74	Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease. JCI Insight, 2017, 2, .	5.0	37
75	D21â€Longitudinal compensation in the cognitive network in huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.1-A42.	1.9	0
76	Introduction to the JINS Special Issue: Preclinical Prediction. Journal of the International Neuropsychological Society, 2016, 22, 951-955.	1.8	0
77	Subjective sleep problems in Huntington's disease: A pilot investigation of the relationship to brain structure, neurocognitive, and neuropsychiatric function. Journal of the Neurological Sciences, 2016, 364, 148-153.	0.6	29
78	HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Quality of Life Research, 2016, 25, 2441-2455.	3.1	39
79	Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology, 2016, 87, 2283-2283.	1.1	1
80	D20â€Operationalising compensation over time in neurodegenerative disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A41.2-A41.	1.9	0
81	D22â€Compensation in preclinical huntington's disease: evidence from the track-on HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.2-A42.	1.9	0
82	Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data. British Journal of Psychiatry, 2016, 208, 571-578.	2.8	43
83	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. Journal of the International Neuropsychological Society, 2016, 22, 595-608.	1.8	44
84	Computational modeling for addiction medicine. Progress in Brain Research, 2016, 224, 53-65.	1.4	24
85	Cognitive assessment strategies in Huntington's disease research. Journal of Neuroscience Methods, 2016, 265, 19-24.	2.5	18
86	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). JAMA Neurology, 2016, 73, 102.	9.0	38
87	Decision-making in Psychopathy. Psychiatry, Psychology and Law, 2016, 23, 521-537.	1.2	7
88	Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 545-549.	1.9	69
89	Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. PLOS Currents, 2016, 8, .	1.4	6
90	Dual task performance in Huntington's disease: A comparison of choice reaction time tasks Neuropsychology, 2015, 29, 703-712.	1.3	7

#	Article	IF	CITATIONS
91	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine, 2015, 2, 1420-1429.	6.1	122
92	Functional Brain Correlates of Neuropsychiatric Symptoms in Presymptomatic Huntington's Disease: The IMAGE-HD Study. Journal of Huntington's Disease, 2015, 4, 325-332.	1.9	10
93	Dual Task Performance May be a Better Measure of Cognitive Processing in Huntington's Disease than Traditional Attention Tests. Journal of Huntington's Disease, 2015, 4, 119-130.	1.9	6
94	Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study. PLoS ONE, 2015, 10, e0117593.	2.5	30
95	Hippocampal 5-HT1A Receptor and Spatial Learning and Memory. Frontiers in Pharmacology, 2015, 6, 289.	3.5	67
96	Longitudinal change in white matter microstructure in Huntington's disease: The IMAGE-HD study. Neurobiology of Disease, 2015, 74, 406-412.	4.4	89
97	Effects of task difficulty during dual-task circle tracing in Huntington's disease. Journal of Neurology, 2015, 262, 268-276.	3.6	12
98	Feasibility of use of probabilistic reversal learning and serial reaction time tasks in clinical trials of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 894-898.	2.2	12
99	An improved cognitive model of the Iowa and Soochow Gambling Tasks with regard to model fitting performance and tests of parameter consistency. Frontiers in Psychology, 2015, 6, 229.	2.1	26
100	Utility of self-report and performance-based measures of risk for predicting driving behavior in young people. Personality and Individual Differences, 2015, 86, 184-188.	2.9	12
101	Psychopathic Personality Traits and Iowa Gambling Task Performance in Incarcerated Offenders. Psychiatry, Psychology and Law, 2015, 22, 134-144.	1.2	13
102	Cognitive interventions to enhance neural compensation in Huntington's disease. Neurodegenerative Disease Management, 2015, 5, 155-164.	2.2	27
103	Functional changes during working memory in Huntington's disease: 30-month longitudinal data from the IMAGE-HD study. Brain Structure and Function, 2015, 220, 501-512.	2.3	61
104	Differential effects of social stress on laboratory-based decision-making are related to both impulsive personality traits and gender. Cognition and Emotion, 2015, 29, 1475-1485.	2.0	12
105	Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease. Brain, 2015, 138, 3327-3344.	7.6	96
106	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia, 2015, 79, 138-146.	1.6	56
107	Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 39-47.	10.2	112
108	Data from 617 Healthy Participants Performing the Iowa Gambling Task: A "Many Labs―Collaboration. , 2015, 3, .		15

#	Article	IF	CITATIONS
109	Functional magnetic resonance imaging of working memory in Huntington's disease: Crossâ€sectional data from the IMAGEâ€HD study. Human Brain Mapping, 2014, 35, 1847-1864.	3.6	60
110	HDâ€CAB: A cognitive assessment battery for clinical trials in Huntington's disease ^{1,2,3} . Movement Disorders, 2014, 29, 1281-1288.	3.9	73
111	Movement sequencing in Huntington disease. World Journal of Biological Psychiatry, 2014, 15, 459-471.	2.6	14
112	Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study. Journal of Psychiatry and Neuroscience, 2014, 39, 87-96.	2.4	63
113	Response to <scp>T</scp> urner. Addiction, 2014, 109, 1139-1140.	3.3	1
114	Strategic and nonâ€strategic problem gamblers differ on decisionâ€making under risk and ambiguity. Addiction, 2014, 109, 1128-1137.	3.3	58
115	Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 2014, 10, 204-216.	10.1	873
116	Age and task difficulty differences in dual tasking using circle tracing and serial subtraction tasks. Aging Clinical and Experimental Research, 2014, 26, 201-211.	2.9	13
117	The cognitive burden in Huntington's disease: Pathology, phenotype, and mechanisms of compensation. Movement Disorders, 2014, 29, 673-683.	3.9	116
118	Self-reported impulsivity and inhibitory control in problem gamblers. Journal of Clinical and Experimental Neuropsychology, 2014, 36, 144-157.	1.3	30
119	Regret in the context of unobtained rewards in criminal offenders. Cognition and Emotion, 2014, 28, 913-925.	2.0	6
120	White matter connectivity reflects clinical and cognitive status in Huntington's disease. Neurobiology of Disease, 2014, 65, 180-187.	4.4	85
121	The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease. Journal of Huntington's Disease, 2014, 3, 197-207.	1.9	8
122	To simulate or not? Comment on Steingroever, Wetzels, and Wagenmakers (2014) Decision, 2014, 1, 184-191.	0.5	6
123	Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Human Brain Mapping, 2013, 34, 519-529.	3.6	113
124	The structural correlates of functional deficits in early huntington's disease. Human Brain Mapping, 2013, 34, 2141-2153.	3.6	75
125	The relationship between cortisol and verbal memory in the early stages of Huntington's disease. Journal of Neurology, 2013, 260, 891-902.	3.6	19
126	Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease. Psychiatry Research, 2013, 207, 118-126.	3.3	45

#	Article	lF	CITATIONS
127	Cortisol and depression in pre-diagnosed and early stage Huntington's disease. Psychoneuroendocrinology, 2013, 38, 2439-2447.	2.7	40
128	Concurrent Validity of The Psychopathic Personality Inventory–Revised and The Psychopathy Checklist. Criminal Justice and Behavior, 2013, 40, 802-813.	1.8	11
129	Functional andconnectivity changes during working memory inHuntington's disease: 18month longitudinal data from the IMAGE-HD study. Brain and Cognition, 2013, 83, 80-91.	1.8	57
130	Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: The IMAGE-HD study. Neurobiology of Disease, 2013, 51, 82-92.	4.4	80
131	Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: The IMAGE-HD study. Experimental Neurology, 2013, 239, 218-228.	4.1	85
132	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurology, The, 2013, 12, 637-649.	10.2	704
133	Magnetization Transfer Imaging in Premanifest and Manifest Huntington Disease: A 2-Year Follow-Up. American Journal of Neuroradiology, 2013, 34, 317-322.	2.4	19
134	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 517-526.	1.9	29
135	Quality of Life in Huntington's Disease: A Comparative Study Investigating the Impact for those with Pre-Manifest and Early Manifest Disease, and their Partners. Journal of Huntington's Disease, 2013, 2, 159-175.	1.9	43
136	Computational Modeling Reveals Distinct Effects of HIV and History of Drug Use on Decision-Making Processes in Women. PLoS ONE, 2013, 8, e68962.	2.5	42
137	Dual Task Performance in Normal Aging: A Comparison of Choice Reaction Time Tasks. PLoS ONE, 2013, 8, e60265.	2.5	37
138	Multi-Modal Neuroimaging in Premanifest and Early Huntington's Disease: 18 Month Longitudinal Data from the IMAGE-HD Study. PLoS ONE, 2013, 8, e74131.	2.5	74
139	Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 687-694.	1.9	120
140	Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. International Journal of Neuropsychopharmacology, 2012, 15, 883-896.	2.1	105
141	Magnetization Transfer Imaging in Premanifest and Manifest Huntington Disease. American Journal of Neuroradiology, 2012, 33, 884-889.	2.4	23
142	Speech acoustic markers of early stage and prodromal Huntington's disease: A marker of disease onset?. Neuropsychologia, 2012, 50, 3273-3278.	1.6	74
143	Comparing the Iowa and Soochow Gambling Tasks in Opiate Users. Frontiers in Neuroscience, 2012, 6, 34.	2.8	20
144	Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 97-106.	1.9	15

#	Article	IF	CITATIONS
145	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology, The, 2012, 11, 42-53.	10.2	479
146	Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Human Brain Mapping, 2012, 33, 203-212.	3.6	127
147	Neurocognitive signs in prodromal Huntington disease Neuropsychology, 2011, 25, 1-14.	1.3	341
148	The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 567-579.	1.3	52
149	Visuomotor integration deficits precede clinical onset in Huntington's disease. Neuropsychologia, 2011, 49, 264-270.	1.6	49
150	Propensity for risk taking and trait impulsivity in the Iowa Gambling Task. Personality and Individual Differences, 2011, 50, 492-495.	2.9	70
151	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology, The, 2011, 10, 31-42.	10.2	530
152	The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Movement Disorders, 2011, 26, 1684-1690.	3.9	56
153	Evidence for sex differences in the loudness dependence of the auditory evoked potential in humans. Human Psychopharmacology, 2011, 26, 172-176.	1.5	18
154	Estimating Premorbid IQ in the Prodromal Phase of a Neurodegenerative Disease. Clinical Neuropsychologist, 2011, 25, 757-777.	2.3	15
155	Assessment of Cognitive Symptoms in Prodromal and Early Huntington Disease. PLOS Currents, 2011, 3, RRN1250.	1.4	13
156	F24â€Differences in companion and subject ratings of subjects' behaviour using the frontal systems behaviour scale (FrSBe)- findings from the track-hd study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A30.2-A30.	1.9	1
157	HO4â€The relationship of hypothalamic pituitary adrenal axis dysfunction to mood and cognitive changes in the early stages of Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A34.3-A35.	1.9	0
158	H01â€Significant biological and clinical change detected over 1 year in premanifest and early stage Huntington's disease in the TRACK-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A33.2-A33.	1.9	0
159	F04â€Quality of life in Huntington's disease: a comparative study investigating the impact on spouses of those with premanifest and early disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A23.3-A24.	1.9	0
160	Self-paced timing detects and tracks change in prodromal Huntington disease Neuropsychology, 2010, 24, 435-442.	1.3	79
161	I07â€Image-HD: a functional magnetic resonance imaging study of spatial working memory in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A38.1-A38.	1.9	0
162	I06â€Correlations between structural damage and functional deficits in early Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A37.2-A37.	1.9	0

#	Article	IF	CITATIONS
163	G03â€Visuomotor integration deficits in premanifest and early manifest Huntington's disease in the TRACK-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A31.3-A32.	1.9	0
164	Electrophysiological measures as potential biomarkers in Huntington's disease: Review and future directions. Brain Research Reviews, 2010, 64, 177-194.	9.0	42
165	The loudness dependence auditory evoked potential is insensitive to acute changes in serotonergic and noradrenergic neurotransmission. Human Psychopharmacology, 2010, 25, 423-427.	1.5	18
166	Sequential learning models for the Wisconsin card sort task: Assessing processes in substance dependent individuals. Journal of Mathematical Psychology, 2010, 54, 5-13.	1.8	42
167	Cognitive mechanisms underlying risky decision-making in chronic cannabis users. Journal of Mathematical Psychology, 2010, 54, 28-38.	1.8	152
168	Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology, 2010, 75, 2150-2160.	1.1	124
169	"Frontal―Behaviors Before the Diagnosis of Huntington's Disease and Their Relationship to Markers of Disease Progression: Evidence of Early Lack of Awareness. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 196-207.	1.8	147
170	Oxytocin Attenuates Amygdala Reactivity to Fear in Generalized Social Anxiety Disorder. Neuropsychopharmacology, 2010, 35, 2403-2413.	5.4	427
171	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, The, 2009, 8, 791-801.	10.2	856
172	Visual scanning and cognitive performance in prediagnostic and earlyâ€stage Huntington's disease. Movement Disorders, 2009, 24, 533-540.	3.9	11
173	Motor abnormalities in premanifest persons with Huntington's disease: The PREDICTâ€HD study. Movement Disorders, 2009, 24, 1763-1772.	3.9	128
174	Similar processes despite divergent behavior in two commonly used measures of risky decision making. Journal of Behavioral Decision Making, 2009, 22, 435-454.	1.7	52
175	Tenâ€year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Movement Disorders, 2008, 23, 1830-1836.	3.9	52
176	Comparison of Decision Learning Models Using the Generalization Criterion Method. Cognitive Science, 2008, 32, 1376-1402.	1.7	180
177	Neurocognitive deficits related to poor decision making in people behind bars. Psychonomic Bulletin and Review, 2008, 15, 44-51.	2.8	75
178	Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 874-880.	1.9	696
179	Visual perception in prediagnostic and early stage Huntington's disease. Journal of the International Neuropsychological Society, 2008, 14, 446-453.	1.8	19
180	Obsessive and Compulsive Symptoms in Prediagnosed Huntington's Disease. Journal of Clinical Psychiatry, 2008, 69, 1758-1765.	2.2	61

#	Article	IF	CITATIONS
181	Specific Psychiatric Manifestations Among Preclinical Huntington Disease Mutation Carriers. Archives of Neurology, 2007, 64, 116.	4.5	68
182	Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain, 2007, 130, 1732-1744.	7.6	181
183	Are Cognitive Changes Progressive in Prediagnostic HD?. Cognitive and Behavioral Neurology, 2007, 20, 212-218.	0.9	24
184	Psychiatric Symptoms in Huntington's Disease before Diagnosis: The Predict-HD Study. Biological Psychiatry, 2007, 62, 1341-1346.	1.3	363
185	Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia, 2007, 45, 1767-1776.	1.6	122
186	Increased cortical recruitment in Huntington's disease using a Simon task. Neuropsychologia, 2007, 45, 1791-1800.	1.6	77
187	Preparing for Preventive Clinical Trials. Archives of Neurology, 2006, 63, 883.	4.5	292
188	Saccades in presymptomatic and early stages of Huntington disease. Neurology, 2006, 67, 394-399.	1.1	115
189	Motivational processes and autonomic responsivity in Asperger's disorder: Evidence from the Iowa Gambling Task. Journal of the International Neuropsychological Society, 2006, 12, 668-676.	1.8	97
190	Psychological Processes Underlying Risky Decisions in Drug Abusers Psychology of Addictive Behaviors, 2005, 19, 148-157.	2.1	98
191	Activation of conflicting responses in Parkinson's disease: evidence for degrading and facilitating effects on response time. Neuropsychologia, 2005, 43, 1033-1043.	1.6	51
192	Individual differences in the response to forgone payoffs: an examination of high functioning drug abusers. Journal of Behavioral Decision Making, 2005, 18, 97-110.	1.7	46
193	Cognitive impairment and dementia in basal ganglia disorders. Current Neurology and Neuroscience Reports, 2005, 5, 355-363.	4.2	18
194	Using Cognitive Models to Map Relations Between Neuropsychological Disorders and Human Decision-Making Deficits. Psychological Science, 2005, 16, 973-978.	3.3	274
195	Neurocognitive insights into substance abuse. Trends in Cognitive Sciences, 2005, 9, 195-201.	7.8	205
196	Cognitive modeling analysis of decision-making processes in cocaine abusers. Psychonomic Bulletin and Review, 2004, 11, 742-747.	2.8	138
197	Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vision Research, 2004, 44, 2729-2736.	1.4	66
198	Reduced autonomic responsiveness to gambling task losses in Huntington's disease. Journal of the International Neuropsychological Society, 2004, 10, 239-245.	1.8	48

#	Article	IF	CITATIONS
199	Visual function in Huntington's disease patients and presymptomatic gene carriers. Movement Disorders, 2003, 18, 1027-1034.	3.9	12
200	Factor Analysis of the Frontal Systems Behavior Scale (FrSBe). Assessment, 2003, 10, 79-85.	3.1	179
201	Frontal Behavioral Syndromes and Functional Status in Probable Alzheimer Disease. American Journal of Geriatric Psychiatry, 2003, 11, 683-686.	1.2	47
202	Frontal Behavioral Syndromes and Functional Status in Probable Alzheimer Disease. American Journal of Geriatric Psychiatry, 2003, 11, 683-686.	1.2	36
203	Enhanced negative priming in Parkinson's disease Neuropsychology, 2002, 16, 242-250.	1.3	21
204	Divergent findings regarding negative priming in Parkinson's disease: A comment of Filoteo et al. (2000) and Wylie and Stout (2000) Neuropsychology, 2002, 16, 251-253.	1.3	7
205	A contribution of cognitive decision models to clinical assessment: Decomposing performance on the Bechara gambling task Psychological Assessment, 2002, 14, 253-262.	1.5	368
206	A contribution of cognitive decision models to clinical assessment: Decomposing performance on the Bechara gambling task Psychological Assessment, 2002, 14, 253-262.	1.5	199
207	Enhanced negative priming in Parkinson's disease. Neuropsychology, 2002, 16, 242-50.	1.3	10
208	Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiology of Aging, 2001, 22, 581-594.	3.1	809
209	Risky decision making in Huntington's disease. Journal of the International Neuropsychological Society, 2001, 7, 92-101.	1.8	123
210	Influence of Competing Distractors on Response Selection in Huntington's Disease and Parkinson's Disease. Cognitive Neuropsychology, 2001, 18, 643-653.	1.1	15
211	Clinical markers of early disease in persons near onset of Huntington's disease. Neurology, 2001, 57, 658-662.	1.1	197
212	Neurobehaviors and psychotic symptoms in Alzheimer's disease. Journal of the International Neuropsychological Society, 2000, 6, 815-820.	1.8	57
213	Stone Tool-Making and Brain Activation: Position Emission Tomography (PET) Studies. Journal of Archaeological Science, 2000, 27, 1215-1223.	2.4	127
214	Frontal neuropsychiatric syndromes in Huntington's disease (HD) and Parkinson's disease (PD). Archives of Clinical Neuropsychology, 1999, 14, 133-133.	0.5	2
215	Assessing Frontal Lobe Behavioral Syndromes with the Frontal Lobe Personality Scale. Assessment, 1999, 6, 269-284.	3.1	278
216	Regional cerebral volume loss associated with verbal learning and memory in dementia of the Alzheimer type Neuropsychology, 1999, 13, 188-197.	1.3	44

#	Article	IF	CITATIONS
217	Discourse Comprehension in Huntington's and Parkinson's Diseases. American Journal of Speech-Language Pathology, 1999, 8, 137-148.	1.8	53
218	Longitudinal Cognitive and Motor Changes Among Presymptomatic Huntington Disease Gene Carriers. Archives of Neurology, 1999, 56, 563.	4.5	99
219	Regional cerebral volume loss associated with verbal learning and memory in dementia of the Alzheimer type Neuropsychology, 1999, 13, 188-197.	1.3	19
220	Relationship of neuropsychological and MRI measures to age of onset of schizophrenia ^a . Acta Psychiatrica Scandinavica, 1998, 98, 156-164.	4.5	56
221	Progressive Cerebral Volume Loss in Human Immunodeficiency Virus Infection. Archives of Neurology, 1998, 55, 161.	4.5	176
222	Frontal Behavioral Syndromes in Cortical and Subcortical Dementia. Assessment, 1996, 3, 327-337.	3.1	55
223	Association of Dementia Severity With Cortical Gray Matter and Abnormal White Matter Volumes in Dementia of the Alzheimer Type. Archives of Neurology, 1996, 53, 742-749.	4.5	96
224	Decline in working memory associated with HIV infection. Psychological Medicine, 1995, 25, 1221-1232.	4.5	69
225	Do Patients With HIV-Associated Minor Cognitive/Motor Disorder Exhibit a "Subcortical―Memory Profile? Evidence Using the California Verbal Learning Test. Assessment, 1995, 2, 151-165.	3.1	43
226	Verbal memory performance of patients with human immunodeficiency virus infection: Evidence of subcortical dysfunction. Journal of Clinical and Experimental Neuropsychology, 1994, 16, 508-523.	1.3	120
227	An animal model for measuring behavioral responses to anxiogenic and anxiolytic manipulations. Pharmacology Biochemistry and Behavior, 1994, 47, 459-465.	2.9	37
228	Depression and anxiety: Role of the locus coeruleus and corticotropin-releasing factor. Brain Research Bulletin, 1994, 35, 561-572.	3.0	149
229	Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. Journal of Neuroscience, 1990, 10, 176-183.	3.6	380
230	Marital quality, marital disruption, and immune function Psychosomatic Medicine, 1987, 49, 13-34.	2.0	557
231	Stress-related immune suppression: Health implications. Brain, Behavior, and Immunity, 1987, 1, 7-20.	4.1	352
232	Stress depresses interferon production by leukocytes concomitant with a decrease in natural killer cell activity Behavioral Neuroscience, 1986, 100, 675-678.	1.2	233
233	Modulation of cellular immunity in medical students. Journal of Behavioral Medicine, 1986, 9, 5-21.	2.1	363
234	Stress depresses interferon production by leukocytes concomitant with a decrease in natural killer cell activity. Behavioral Neuroscience, 1986, 100, 675-678	1.2	103

#	Article	IF	CITATIONS
235	Psychosocial enhancement of immunocompetence in a geriatric population Health Psychology, 1985, 4, 25-41.	1.6	326
236	Stress-related impairments in cellular immunity. Psychiatry Research, 1985, 16, 233-239.	3.3	218